PMCB
PharmaCyte Biotech·NASDAQ
--
--(--)
--
--(--)
6.93 / 10
Outperform
Fund-flow analysis reveals a 6.93/10 score with positive capital movement across Small, Medium, Large, and Extra-large baskets, though the overall trend is labeled negative in the data, hinting at short-term volatility. There are no analyst ratings available (ana_eval = -1). The combination of decent fund inflows and lack of analyst coverage results in a neutral sentiment rating, underscoring the need for investors to rely more on intrinsic and technical analysis.
Fund Flow Rating
Is money flowing into or out of PMCB?
- PMCB holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.93/10 (Outperform).
